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Abstract
Background: Besides existing artemisinin-based combination therapies, alternative safe, effective and affordable drug
combinations against falciparum malaria are needed. Methylene blue (MB) was the first synthetic antimalarial drug ever
used, and recent studies have been promising with regard to its revival in malaria therapy. The objective of this study was to
assess the safety and efficacy of two MB-based malaria combination therapies, MB–artesunate (AS) and MB–amodiaquine
(AQ), compared to the local standard of care, AS-AQ, in Burkina Faso.
Methods and Findings: Open-label randomised controlled phase II study in 180 children aged 6–10 years with
uncomplicated falciparum malaria in Nouna, north-western Burkina Faso. Follow-up was for 28 days and analysis by
intention-to-treat. The treatment groups were similar in baseline characteristics and there was only one loss to follow-up. No
drug-related serious adverse events and no deaths occurred. MB-containing regimens were associated with mild vomiting
and dysuria. No early treatment failures were observed. Parasite clearance time differed significantly among groups and was
the shortest with MB-AS. By day 14, the rates of adequate clinical and parasitological response after PCR-based correction
for recrudescence were 87% for MB-AS, 100% for MB-AQ (p=0.004), and 100% for AS-AQ (p=0.003). By day 28, the
respective figure was lowest for MB-AS (62%), intermediate for the standard treatment AS-AQ (82%; p=0.015), and highest
for MB-AQ (95%; p,0.001; p=0.03).
Conclusions: MB-AQ is a promising alternative drug combination against malaria in Africa. Moreover, MB has the potential
to further accelerate the rapid parasite clearance of artemisinin-based combination therapies. More than a century after the
antimalarial properties of MB had been described, its role in malaria control deserves closer attention.
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Introduction
Early diagnosis and prompt treatment with an effective antima-
larial medicine remains the mainstay of malaria control in sub-
Saharan Africa (SSA) [1]. This strategy is now complicated by the
increasing resistance development of Plasmodium falciparum to
accessible and affordable first-line drugs such as chloroquine (CQ)
and sulfadoxine/pyrimethamine (SP) in most countries of SSA [1–3].
Treatment with effective drugs as combinations has eventually
become a paradigm in malaria control, with the particular aim to
delay and possibly reverse the development of drug resistance [4–
9]. Artemisinin-based combination therapy (ACT) has proved
highly effective in a number of field trials [10–16]. However, ACT
is not readily available and often prohibitively expensive in SSA
[6,9,17,18]. Moreover, resistance may develop also against ACT,
particularly in conjunction with a long-lasting, non-artemisinin
partner drug [1,19–20]. Worrying evidence has already been
provided that resistance to artemisinins may be selected in vivo by
uncontrolled use of artemisinins or in combination with ineffective
partner drugs [21,22]. Finally, a number of alternative antimalar-
ial combinations have been shown to be of at least similar efficacy
compared to ACT [16,23–26].
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1630Methylene blue (MB), the first synthetic drug ever used against
malaria [27], has received renewed attention in recent years [28].
MB is a subversive substrate and specific inhibitor of P. falciparum
glutathione reductase, it inhibits the heme polymerization within
the parasite’s food vacuole, and prevents methaemoglobinaemia in
clinical malaria [28,29]. MB in combination with CQ has been
shown to be safe in a West-African population with a high
prevalence of G6PD deficiency [30–32]. However, due to intense
CQ resistance in the study area, this combination was shown not
to be sufficiently effective against malaria in young children of
Burkina Faso [31,32]. This is in accord with the impaired efficacy
of ACT regimens comprising non-artemisinin partner drugs
affected by high grade resistance [10,26,33].
Amodiaquine (AQ) has remained remarkably effective in many
SSA countries despite emerging CQ resistance [11,34–37]. It is
considered a candidate partner drug both in ACT and in non-
artemisinin drug combinations [1]. The combination MB-AQ
could thus become an alternative to ACT. Likewise, MB-AS might
have a role in combination treatment, particularly when
considering that synergy with artemisinin derivatives has been
demonstrated in a recent in vitro study [38].
Against this background, the safety and efficacy of MB
combined with artesunate (AS) and of MB combined with AQ
was studied in a controlled trial in Burkina Faso.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study area
The study was conducted in October/November 2006 in the
urban research zone of the Centre de Recherche en Sante ´ de Nouna
(CRSN) in Nouna Health District, north-western Burkina Faso.
The area is highly endemic for malaria with most clinical cases
occurring during or briefly after the rainy season which lasts from
June until October [39]. Although ACT has become the official
first-line treatment for uncomplicated malaria in Burkina Faso
since 2005, malaria control in the study area continues to be
mainly based on home treatment with CQ [18,40].
Study design and objectives
The study was designed as a randomized controlled phase II
trial. The study was open label, with blinding only for the
microscopists involved. The primary objective was to investigate
the safety of the combinations MB-AS and MB-AQ in children
with uncomplicated falciparum malaria. The secondary objective
was to determine the efficacy of these MB-based combinations in
the treatment of children with uncomplicated falciparum malaria.
The primary end point of the study was the incidence of observed
and self-reported adverse events over the 28 days observation
period. Secondary end points were: treatment outcomes until day
14 and day 28 of follow-up, i.e. adequate clinical and
parasitological response (ACPR), early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure (LPF), fever
clearance time, parasite clearance time, and hematocrit at D28
compared to baseline [41]. Study participants with LCF and those
with LPF on D28 received rescue treatment with artemether-
lumefantrine (CoArtemH).
Study population
The community was informed on the project, and mothers with
febrile children were invited to come to fever measurement points
(specific private houses) in Nouna town (population, 25 000).
Children who were considered eligible for the study (acute febrile
disease, age between 6 and 10 years) were referred to the Nouna
district hospital outpatient clinic for further examinations.
Inclusion criteria were: age 6–10 years, ability to swallow
tablets, uncomplicated falciparum malaria (axillary temperature
$37.5uC and $1,000 P. falciparum asexual parasites per mL blood),
and written informed consent given by the parents/caretakers.
The age range criterion results from the absence - at the time of
the study - of a liquid, taste-masked MB formulation, thus, patients
needed to be able to take coated MB tablets (Urolene BlueH, Star
Pharmaceuticals, USA). Exclusion criteria were signs of severe
malaria, any apparent other disease, and malaria treatment –
except CQ - with western drugs and/or antibiotics with
antimalarial potency during the preceding week.
Randomization
Treatment was randomly assigned according to study identifi-
cation numbers (computer-generated randomly permutated
codes). A sealed envelope containing the identification numbers
was opened after finalisation of the examination in the hospital
and after informed consent was given.
Study intervention
180 children were assigned to receive either MB-AS, MB-AQ,
or AS-AQ, AS-AQ being the official first-line antimalarial in
Burkina Faso. MB (Urolene BlueH, Star Pharmaceuticals, USA)
was given at a dose of 10 mg per kilogram of body weight twice
daily over three days. AS (Artesunate, Guilin Pharmaceuticals Co.,
Ltd., PR China) was given at a dose of 4 mg per kilogram of body
weight once daily over three days. AQ (Essential Drug Store,
Ministry of Health, Burkina Faso) was given at a dose of 10 mg per
kilogram of body weight once daily over three days. The study
drugs were administered under direct observation by study nurses
(morning, at hospital) or field workers (evening, at home). In case
of vomiting within the first 30 minutes the treatment was repeated.
If vomiting occurred again, the patient was excluded and referred
to the paediatrics department of the hospital. Children with fever
$38.5uC received a standard dose of 10 mg per kilogram
paracetamol tablets every 6 hours (Essential Drug Store, Ministry
of Health, Burkina Faso) until the symptoms subsided.
Follow-up
Follow-up of study children was for 28 days using a slightly
modified version of the latest WHO protocol on antimalarial drug
efficacytesting[41].Childrenwereincludediftheyhadatleast1,000
P.falciparumparasitesandwerefollowedupondays1,2,3,7,14,and
28. Mothers and caretakers were encouraged to come back at any
time between scheduled visits in case of unforeseen symptoms.
Laboratory examinations
A finger-prick blood sample was taken on days 0, 2, 3, 7, 14,
and 28, and during unscheduled visits. From this, malaria
parasitaemia and haematocrit values were determined using
standard CRSN procedures [39]. Thick and thin blood films
were examined by two experienced laboratory technicians
supervised by one of the investigators (BC). Asexual parasites
were counted on thick blood films against 200 white blood cells
(WBCs) and parasite density was calculated assuming an average
WBC count of 10,000/mL. Slides were declared negative if no
parasites were seen in 400 fields on the thick film. For quality
control, a 10% random sample of blood films is regularly cross
checked at the Heidelberg School of Tropical Medicine [39].
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After shipment to the Institute of Tropical Medicine and
International Health Berlin, DNA was extracted using commercial
kits (QIAmp, Qiagen, Germany). Differentiation of recrudescences
from new infections was achieved by comparing PCR-generated P.
falciparum msp1 and msp2 genotype patterns in matched pairs of
isolates obtained on admission and on the day of reappearance of
parasitaemia [42].
Statistical analysis
Thestudywasdesignedto have astatistical powerof80%inorder
to detect a difference in the number of adverse events of at least 20%
among study groups that was significant at the five percent level.
Losses to follow-up and dropouts due to other reasons were
considered treatment failures in an intention-to-treat manner.
The Chi square test (Chi) was used to compare proportions, and
the non-parametric Wilcoxon-Mann-Whitney test (WMW) to
compare metric or ordinal data. When possible, estimates and the
corresponding 95% confidence interval are given.
The closed testing procedure [43] was used to adjust for
multiple testing when performing two group comparisons in a
three-armed trial. In case of three groups, this procedure performs
in a global test for the nullhypothesis ‘‘No difference between the
three groups’’. In case of a significant result, the three pairwise
comparisons are performed on a five percent level. In the multiple
testing situation the procedure guarantees an overall level of 5%.
Figure 1. Flow chart of study patients. Explanations: (1) Of 244 children assessed for eligibility, 64 were excluded because of not meeting
inclusion criteria; (2) In group MB-AS, one child was lost to follow-up because of family out-migration after day 7; (3) all children followed up until the
end of the study were included into the analysis
doi:10.1371/journal.pone.0001630.g001
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Institute Inc, Cary, NC, USA).
Ethical aspects
The study protocol was approved by the Ethics Committee of
the Medical Faculty at Heidelberg University and the National
Ethics Committee of Burkina Faso. Caretakers were asked for their
written consent after having received detailed information from a
study nurse about all known risks and benefits of the study through
translation of a detailed research consent form into the local
language,
Results
Enrolment and baseline characteristics of study children
Of 1 200 children seen at the fever measurement points, 244
children were referred to hospital for assessment, and of those 180
(61 MB-AS, 58 MB-AQ, 61 AS-AQ) were included into the study
(Figure 1). These children form the a priori defined full analysis set
(FAS) for the intention-to-treat analysis. There was one loss to
follow-up due to out-migration from the study area (MB-AS
group, after day 7). At enrolment, the demographic and clinical
characteristics of the participants in the three study groups were
similar, except a small but significant difference in weight (Table 1).
Safety of study drugs
There was no case of death but one serious adverse event over
the 28 days follow-up period. It occurred in the AS-AQ group as a
brief hospitalisation late at night on day 0 due to severe vomiting.
This child was not considered a treatment failure and thus not
excluded from the further analysis.
Adverse events are shown in Table 2. Compared to the two MB-
receiving study groups, children in the AS-AQ group had fewer
adverse events. This was mainly due to the high rates of vomiting
and dysuria in both MB-receiving groups. Vomiting in the MB-
receiving groups was mild and when it occurred it did so regularly
between one and two hours after the intake of the study drugs. In the
81/119 (68%) children of the MB-receiving groups who experienced
vomiting, its frequency was 1.5 (range 1–4) over the three days
treatment period. After a thorough instruction of all mothers and
caretakers to always give some food before drug administration, the
frequency of vomiting decreased significantly in both MB-receiving
groups (data not shown). Mild dysuria in the MB-receiving groups
usually subsided after day 4. In only two cases, dysuria was reported
to continue until day 7 and day 14, respectively.
Efficacy of study drugs
Efficacy results are given in Table 3. No ETF was observed. By
day 14, the ACPR rate after PCR-based correction for
recrudescence was significantly lower in the MB-AS group (87%)
compared to the two AQ-receiving groups (100%).
Similarily, by day 28, the rate of ACPR without correction was
significantly lower in the MB-AS group (28%) compared to the
groups MB-AQ (79%) and AS-AQ (66%). During the 28 days of
follow-up, exclusively new genotypes, i.e. re-infections, were more
frequent with MB-AS (34.4%; 21/61) than with MB-AQ (15.5%;
9/58; p=0.02) or AQ-AS (16.4%; 10/61; p=0.02). After PCR-
based correction for recrudescence, the ACPR rates increased to
62% (MB-AS), 95% (MB-AQ), and 82% (AS-AQ), differences
being significant among all groups (table 3).
Fever was cleared rapidly in all three groups; only two patients
remained febrile until day 2 in the MB-AS group, and two until
day 1 in the MB-AQ group. However, there were significant
differences in parasite clearance among study groups (table 3):
While in the MB-AS group only 7/61 patients had parasites (range
40–200/mL) on day 2, and this was further reduced to 1/61 (100/
mL) by day 3, in the MB-AQ group, 46/58 patients had parasites
(range 50–5,000/mL) on day 2 and this was reduced to 10/58
(range 40–120/mL) by day 3. Patients receiving AS-AQ showed an
intermediate pattern of parasitaemia prevalence on day 2 (14/61,
range 40–500/mL) and day 3 (3/61, all 40/mL). Parasite clearance
differences were significant when comparing the MB-AS and MB-
AQ groups (p,0.001) as well as the MB-AQ and AS-AQ groups
(p,0.001), and were close to significance when comparing MB-AS
with AS-AQ (p=0.081).
There were no significant changes in median haematocrit values
over time and among groups (data not shown).
Discussion
Treatment with the MB-based combinations was associated
with significantly more adverse events compared to AS-AQ, and
this was caused by the frequent occurrence of vomiting and
dysuria, symptoms already known to be associated with MB tablets
[44]. However, these events were always mild and self-limiting.
Importantly, vomiting was shown to be much reduced by
administering MB together with food which should be the clear
advice in further studies.
Urolene BlueH is a taste-masked MB tablet used for other
indications in patients who are able to swallow tablets. There is
currently no paediatric taste-masked formulation on the market
and the provision of non-masked liquid MB solutions or crushed
tablets dissolved in water is not recommendable as the drug has a
strong bitter-metallic taste [31,32]. Therefore, a taste-masked MB
syrup has recently been developed by our group together with the
group of Prof. Breitkreutz from the University of Du ¨sseldorf in
Germany which currently undergoes clinical testing. Such a
paediatric MB formulation will allow further clinical studies with
Table 1. Characteristics of study children at enrolment
Characteristic MB-AS group (n=61) MB-AQ group (n=58) AS-AQ group (n=61) p-value
Female sex (%) 30 (49) 32 (55) 22 (36) 0.100
Median age in years (range) 7 (6–10) 6 (6–10) 7 (6–10) 0.512
Median weight in kg (range) 20 (14–32) 19 (13–38) 19 (13–33) 0.039
Median haematocrit in % (range) 34 (26–44) 36 (26–42) 34 (24–40) 0.246
Median number of P. falciparum trophozoites/ml (range) 33,000 (1,000–265,050) 28,700 (1,000–200,000) 31,000 (1,000–258,000) 0.529
Median duration of the current disease episode in days (range) 2 (1–7) 2 (1–7) 2 (1–7) 0.488
Reported CQ treatment of current disease episode (%) 6 (10) 12 (21) 10 (16) 0.256
doi:10.1371/journal.pone.0001630.t001
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main risk group of malaria in SSA [1].
Two main results with regard to the efficacy of the MB-based
combinations are provided by the present trial. First, the efficacy
of MB-AQ in the study area is high, and significantly higher than
it is the case for the standard ACT regimen. With 95% ACPR
after 28 days of follow-up, the efficacy of MB-AQ is in the range of
various ACT regimens in SSA [10–13,15,16]. This high cure rate
of MB-AQ might partially result from the comparatively advanced
age of study participants and, consequently, immunity contribut-
ing to parasite elimination. This, however, would not explain the
superiority of MB-AQ over AQ-AS, and, also, suggests that the
striking cure rate of MB-AQ is unlikely to be explained by the
efficacy of AQ alone. A recent trial on AQ in older patients
(median age, 4.2 years) from western Burkina Faso demonstrated a
PCR-corrected ACPR rate of only 82% after 28 days of follow-up
[37]. Similarily, data from 117 children aged five years or less and
treated in Nouna town in 2005 with AQ showed an ACPR rate
after PCR-based correction for recrudescence at day 28 of only
61% (Mandi et al., unpublished). Finally, preliminary results on
the high efficacy of MB monotherapy in semi-immune adults with
falciparum malaria provide further evidence for a substantial
contribution of MB to the efficacy of MB-based combination
therapies (Mu ¨ller et al., unpublished).
Table 2. Adverse events in the three study groups
p-values
MB-AS n=61 MB-AQ n=58 AS-AQ n=61 global MB-AS vs. MB-AQ MB-AS vs. AS-AQ MB-AQ vs. AS-AQ
Vomiting (%) 44 ( 72.1) 37 ( 63.8) 16 ( 26.2) ,0.001 0.329 ,0.001 ,0.001
Dysuria (%) 28 ( 45.9) 37 ( 63.8) 0 ( 0.0) ,0.001 0.050 ,0.001 ,0.001
Headache (%) 4 ( 6.6) 5 ( 8.6) 10 ( 16.4) 0.177 0.670 0.088 0.202
Pruritus (%) 0 ( 0.0) 6 ( 10.3) 0 ( 0.0) 0.001 0.010 1.000 0.010
Bronchitis (%) 4 ( 6.6) 6 ( 10.3) 7 ( 11.5) 0.624 0.457 0.343 0.843
Diarrhoea (%) 1 ( 1.6) 3 ( 5.2) 3 ( 4.9) 0.534 0.285 0.309 0.949
Others (%) 11 ( 18.0) 5 ( 8.6) 18 ( 29.5) 0.014 0.132 0.137 0.004
doi:10.1371/journal.pone.0001630.t002
Table 3. Efficacy outcomes in the three study groups
p-values








- until D2 7 (11.5%) 37 (63.8%) 13 (21.3%) ,0.001 ,0.001 0.081 ,0.001
- until D3 1 (1.6%) 10 (17.2%) 3 (4.9%)
ETF 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.000 1.000 1.000 1.000
LPF( D14)
- without PCR-based correction 6 (9.8%) 0 (0.0%) 1 ( 1.6%) 0.011 0.014 0.052 0.327
- with PCR-based correction 4 (6.6%) 0 (0.0%) 0 (0.0%) 0.018 0.047 0.042 1.000
LPF( D28)
- without PCR-based correction 24 (39.3%) 11 (19.0%) 16 (26.2%) 0.043 0.015 0.123 0.344
- with PCR-based correction 13 (21.3%) 3 (5.2%) 9 (14.8%) 0.038 0.010 0.346 0.083
LTF (D14)
- without PCR-based correction 6 (9.8%) 0 (0.0%) 0 (0.0%) 0.002 0.014 0.012 1.000
- with PCR-based correction 4 (6.6%) 0 (0.0%) 0 (0.0%) 0.018 0.047 0.042 1.000
LTF (D28)
- without PCR-based correction 20 (32.8%) 1 (1.7%) 5 (8.2%) ,0.001 ,0.001 ,0.001 0.107
- with PCR-based correction 10 (16.4%) 0 (0.0%) 2 (3.3%) ,0.001 0.001 0.015 0.164
ACPR (D14)
- without PCR-based correction 49 (80.3%) 58 (100.0%) 60 (98.4%) ,0.001 ,0.001 0.001 0.327
- with PCR-based correction 53 (86.9%) 58 (100.0%) 61 (100.0%) ,0.001 0.004 0.003 1.000
ACPR (D28)
- without PCR-based correction 17 (27.9%) 46 (79.3%) 40 (65.6%) ,0.001 ,0.001 ,0.001 0.094
- with PCR-based correction 38 (62.3%) 55 (94.8%) 50 (82.0%) ,0.001 ,0.001 0.015 0.030
doi:10.1371/journal.pone.0001630.t003
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worse than expected and than it has been reported previously from
other places in West Africa [10,16]. It is currently not clear if this
finding reflects local differences in AQ resistance, a real inferiority
of AS-AQ compared to MB-AQ, or both. Although the AQ used
for this study was taken from a local source, we are confident that
it is of good quality. Drugs from the essential drug store of the
Ministry of Health are regularly quality controlled and a recent
study on the quality of malaria drugs in the Nouna Health District
provided no evidence for quality problems with AQ (Maike Tipke,
unpublished).
Secondly, although performing rather poor in terms of overall
efficacy, MB-AS achieved a more rapid clearance of P. falciparum
parasites than the other two treatment regimes. This provides
evidence in humans for a clinically relevant synergy between an
artemisinin derivative and MB, which has already been shown in
vitro [38]. Adding MB to ACT may thus be an option to further
speed up the rapid parasite clearance conferred by the artemisinin
derivatives [4,6–8].
Likely related to the short elimination half-life of both MB and
AS [32,45], re-infections were more common in children treated
with this combination than in patients receiving treatment
containing AQ. Also, rapid parasite clearance in MB-AS may
interfere with the development of sustained immune mechanisms
preventing re-infections. Similar findings have been observed in
northern Ghana where the fastest regimen in parasite clearance,
SP-AS, produced the highest proportion of re-infections [46].
As MB is both available and affordable, the combination MB-
AQ would be an interesting alternative antimalarial regimen when
shown to be safe and effective in larger multi-centre phase III
studies. Such studies are now planned for in the frame of a public-
private-partnership by our group. Apart from the potential benefit
of another effective antimalarial regimen contributing to a healthy
competition of different regimens on the market, MB can be
considered a re-emerging antimalarial with the potential to be a
valuable partner drug in various ACT and non-artemisinin drug
combinations.
In conclusion, MB-AQ is a promising alternative drug
combination against falciparum malaria in SSA. Moreover, MB
has the potential to further accelerate parasite clearance when
used in ACT. Further studies are needed to define the possible
roles of MB in malaria treatment.
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